Company Overview of Amphion Innovations Plc
Amphion Innovations plc is a venture capital firm specializing in both public and private early stage investments and spun out of universities and corporations. It does not invest in “speculative” technologies requiring long development timeframes or excessive capital investment. It invests in the medical, life sciences, and technology sectors with defensible core intellectual property, know-how and growth potential in very large markets of at least $1 billion in size together with corporations, governments, universities, and entrepreneurs. The firm typically invests in companies with broad-based, proprietary, platform technologies in the areas of pharmacogenomics, proteomics, nutriceuticals...
125 Park Avenue
New York, NY 10017
Founded in 1984
Key Executives for Amphion Innovations Plc
Chief Executive Officer and Executive Director
Total Annual Compensation: $460.0K
President, Chief Financial Officer and Executive Director
Total Annual Compensation: $387.4K
Compensation as of Fiscal Year 2015.
Amphion Innovations Plc Key Developments
Amphion Innovations plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016
Sep 7 16
Amphion Innovations Plc reported unaudited consolidated earnings results for the six months ended June 30, 2016. For the period, revenue was USD 60,000 against USD 267,601 a year ago. Operating loss was USD 1,505,488 against USD 1,254,554 a year ago. Profit before tax was USD 320,027 against USD 33,151,642 a year ago. Profit for the period was USD 320,027 against USD 33,151,642 a year ago. Profit per share basic and diluted was USD 0.00 against USD 0.15 per diluted share a year ago. Net cash used in operating activities was USD 1,714,415 against USD 1,295,620 a year ago.
Amphion Innovations plc Appoints Richard Mansell-Jones as Director and Chairman and Paul Kennedy as Non-Executive Director
Jul 29 16
Amphion Innovations plc announced the appointments to the Board of Mr. Richard Mansell-Jones as Director and Chairman and Mr. Paul Kennedy as Non-executive Director, effective immediately. Richard Mansell-Jones is a former Non-executive Chairman of Amphion, and has great experience of public company leadership and governance. Paul Kennedy has an extensive career in the pharmaceutical industry, occupying senior management positions with major pharmaceutical companies as well as working and investing as an entrepreneur in smaller biotechnology companies.
Amphion Innovations plc Announces Additional Draw Down Facility on its Loan Facility
Jul 13 16
Amphion Innovations plc announced that the company has agreed terms for the draw-down of an additional tranche of $750,000 (an 'Additional Draw') under the loan facility as initially announced on June 5, 2014 (the 'Facility'). The company will receive the proceeds of the Additional Draw immediately. Under the terms of the Additional Draw, nil interest is charged with a repayment amount of $881,250 due on 6 October 2016. The proceeds of the Additional Draw are to be used to partially repay the existing amount due under the Facility and for working capital for Amphion and its Partner Companies. The Additional Draw may be converted into Ordinary Shares in Amphion in accordance with the additional terms of the Facility announced on 29 April 2016. The Additional Draw is to be secured by the Company pledging an additional amount of marketable securities, equivalent in value to $900,000, within 30 days of this announcement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|